Skip to main content
Top

15-05-2024 | Overactive Bladder | Review

Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices

Authors: Una J. Lee, Scott MacDiarmid, Catherine A. Matthews, Emily Gillespie, Kenneth M. Peters

Published in: Advances in Therapy

Login to get access

Abstract

The tibial nerve is an established target for neuromodulation in the management of overactive bladder (OAB) and its associated symptoms, including urge urinary incontinence (UUI). Technologies are currently available to deliver tibial nerve stimulation (TNS) through percutaneous devices or through implantable devices. The benefits and safety of percutaneous TNS have led to it as a guideline-recommended therapy. However, patient compliance is limited by the burden of weekly office visits and the need for maintenance treatments. Further, insurance often only covers a limited number of lifetime visits for percutaneous TNS. These factors and others have led to the development, study, and utilization of implantable TNS devices. Implantable TNS devices deliver the same therapeutic mechanism of action for nerve stimulation with a permanent implanted device that provides at-home stimulation rather than in-office therapy delivery. Additionally, there is an added potential for dynamic and patient-centered stimulation. There is a large body of high-quality evidence published for TNS, including numerous randomized controlled trials published on percutaneous TNS which have consistently demonstrated superior efficacy to sham and similar efficacy to that of anticholinergic medications. Percutaneous TNS also performs better than conservative therapy including pelvic floor muscle training. The percutaneous and implantable approaches deliver nerve stimulation to the same target nerve, using the same mechanism of action. Therefore, data from randomized trials of percutaneous TNS are informative for implantable TNS devices. At the time of this article’s publication, at least two implantable TNS devices have received marketing authorization from the Food and Drug Administration (FDA). The objective of this review is to discuss the mechanism of action for TNS and summarize the published literature from clinical trials of percutaneous TNS as a foundation of high-quality evidence for implantable devices targeting the tibial nerve.
Literature
1.
go back to reference Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.PubMedCrossRef Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.PubMedCrossRef
2.
go back to reference Coyne K, Payne C, Bhattacharyya S, Revicki D, Thompson C, Corey R, Hunt T. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health J Int Soc Pharmacoecon Outcomes Res. 2004;7:455–63.CrossRef Coyne K, Payne C, Bhattacharyya S, Revicki D, Thompson C, Corey R, Hunt T. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health J Int Soc Pharmacoecon Outcomes Res. 2004;7:455–63.CrossRef
3.
go back to reference Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.PubMedCrossRef Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.PubMedCrossRef
4.
go back to reference Stewart W, Rooyen JV, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMedCrossRef Stewart W, Rooyen JV, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMedCrossRef
5.
go back to reference Coyne KS, Wein A, Nicholson S, Kvasz M, Chen C-I, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.PubMed Coyne KS, Wein A, Nicholson S, Kvasz M, Chen C-I, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.PubMed
6.
8.
go back to reference D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77.PubMedCrossRef D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77.PubMedCrossRef
9.
go back to reference Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–63.PubMedCrossRef Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–63.PubMedCrossRef
10.
go back to reference Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199:779–84.PubMedCrossRef Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199:779–84.PubMedCrossRef
12.
go back to reference Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8.PubMedCrossRef Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8.PubMedCrossRef
14.
go back to reference Al-Danakh A, Safi M, Alradhi M, Almoiliqy M, Chen Q, Al-Nusaif M, Yang X, Al-Dherasi A, Zhu X, Yang D. Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines. Parkinson’s Dis. 2022;2022:2700227. Al-Danakh A, Safi M, Alradhi M, Almoiliqy M, Chen Q, Al-Nusaif M, Yang X, Al-Dherasi A, Zhu X, Yang D. Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines. Parkinson’s Dis. 2022;2022:2700227.
16.
go back to reference Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–9.PubMedCrossRef Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–9.PubMedCrossRef
17.
go back to reference Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PEV, van KPEV. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352–7.PubMedCrossRef Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PEV, van KPEV. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352–7.PubMedCrossRef
18.
go back to reference Cooperberg M, Stoller M. Percutaneous neuromodulation. Urol Clin N Am. 2005;32(71–8):vii. Cooperberg M, Stoller M. Percutaneous neuromodulation. Urol Clin N Am. 2005;32(71–8):vii.
19.
go back to reference Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol-Ren Physiol. 2011;300:F385–92.CrossRef Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol-Ren Physiol. 2011;300:F385–92.CrossRef
20.
go back to reference Choudhary M, Mastrigt R, Asselt E. Effect of tibial nerve stimulation on bladder afferent nerve activity in a rat detrusor overactivity model. Int J Urol. 2016;23:253–8.PubMedCrossRef Choudhary M, Mastrigt R, Asselt E. Effect of tibial nerve stimulation on bladder afferent nerve activity in a rat detrusor overactivity model. Int J Urol. 2016;23:253–8.PubMedCrossRef
21.
22.
go back to reference Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. Int Urogynecol J. 2020;31:865–70.PubMedCrossRef Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. Int Urogynecol J. 2020;31:865–70.PubMedCrossRef
23.
go back to reference Rahnamai MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler J. 2020;26:1274–80.CrossRef Rahnamai MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler J. 2020;26:1274–80.CrossRef
24.
go back to reference Kobashi K, Nitti V, Margolis E, Sand P, Siegel S, Khandwala S, Newman D, MacDiarmid SA, Kan F, Michaud E. A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. Urology. 2019;131:77–82.PubMedCrossRef Kobashi K, Nitti V, Margolis E, Sand P, Siegel S, Khandwala S, Newman D, MacDiarmid SA, Kan F, Michaud E. A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. Urology. 2019;131:77–82.PubMedCrossRef
26.
go back to reference Chermansky C, Schurch B, Rahnamai M, Averbeck M, Malde S, Mancini V, Valentini F, Sahai A. How can we better manage drug-resistant OAB/DO? ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S46–55.PubMed Chermansky C, Schurch B, Rahnamai M, Averbeck M, Malde S, Mancini V, Valentini F, Sahai A. How can we better manage drug-resistant OAB/DO? ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S46–55.PubMed
27.
go back to reference Marcelissen T, Cornu J-N, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, Rieken M, Rahnama’i MS. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? [Figure presented]. Eur Urol Focus. 2018;4:760–7.PubMedCrossRef Marcelissen T, Cornu J-N, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, Rieken M, Rahnama’i MS. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? [Figure presented]. Eur Urol Focus. 2018;4:760–7.PubMedCrossRef
28.
go back to reference Apostolidis A, Averbeck M, Sahai A, Rahnama’i M, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–93.PubMedCrossRef Apostolidis A, Averbeck M, Sahai A, Rahnama’i M, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–93.PubMedCrossRef
29.
go back to reference Gordon T, Merchant M, Ramm O, Patel M. Factors associated with long-term use of percutaneous tibial nerve stimulation for management of overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2021;27:444–9.PubMedCrossRef Gordon T, Merchant M, Ramm O, Patel M. Factors associated with long-term use of percutaneous tibial nerve stimulation for management of overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2021;27:444–9.PubMedCrossRef
30.
go back to reference Jung CE, Menefee SA, Diwadkar GB. Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence. Int Urogynecol J. 2021;32:617–25.PubMedCrossRef Jung CE, Menefee SA, Diwadkar GB. Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence. Int Urogynecol J. 2021;32:617–25.PubMedCrossRef
31.
go back to reference te DMJ, J.P.F.A. H, van BMR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39:702–6. te DMJ, J.P.F.A. H, van BMR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39:702–6.
32.
go back to reference Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–99.PubMedCrossRef Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–99.PubMedCrossRef
34.
go back to reference Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee K-S, Sahai A, Wein AJ, Andersson K-E. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:PHARMREV-AR-2021-000523. Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee K-S, Sahai A, Wein AJ, Andersson K-E. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:PHARMREV-AR-2021-000523.
38.
go back to reference Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin® for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206:399–408.PubMedCrossRef Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin® for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206:399–408.PubMedCrossRef
39.
go back to reference Lee UJ, Xavier K, Benson K, et al. Rationale and design of an implant procedure and pivotal study to evaluate safety and effectiveness of Medtronic’s tibial neuromodulation device. Contemp Clin Trials Commun. 2023;35: 101198.PubMedPubMedCentralCrossRef Lee UJ, Xavier K, Benson K, et al. Rationale and design of an implant procedure and pivotal study to evaluate safety and effectiveness of Medtronic’s tibial neuromodulation device. Contemp Clin Trials Commun. 2023;35: 101198.PubMedPubMedCentralCrossRef
40.
go back to reference Govier F, Litwiller S, Nitti V, Kreder Jr K, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8.PubMedCrossRef Govier F, Litwiller S, Nitti V, Kreder Jr K, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8.PubMedCrossRef
42.
go back to reference Finazzi-Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, Sciobica F, Marfia GA. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28:320–4.PubMedCrossRef Finazzi-Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, Sciobica F, Marfia GA. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28:320–4.PubMedCrossRef
43.
go back to reference Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, MacDiarmid SA. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.PubMedCrossRef Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, MacDiarmid SA. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.PubMedCrossRef
44.
go back to reference Finazzi-Agr E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184:2001–6.CrossRef Finazzi-Agr E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184:2001–6.CrossRef
45.
go back to reference Lashin A, Eltabey N, Wadie B. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. Int Urol Nephrol. 2021;53:2459–67.PubMedCrossRef Lashin A, Eltabey N, Wadie B. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. Int Urol Nephrol. 2021;53:2459–67.PubMedCrossRef
46.
go back to reference Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M, Italy A. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2016;43:121–6.CrossRef Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M, Italy A. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2016;43:121–6.CrossRef
47.
go back to reference Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.PubMedCrossRef Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.PubMedCrossRef
48.
go back to reference Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75:230–4.CrossRef Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75:230–4.CrossRef
49.
go back to reference Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, Hanzal E. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6.PubMedCrossRef Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, Hanzal E. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6.PubMedCrossRef
50.
go back to reference Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol Off J Braz Soc Urol. 2018;44:102–8.CrossRef Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol Off J Braz Soc Urol. 2018;44:102–8.CrossRef
51.
go back to reference Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017;24:8838–46.PubMed Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017;24:8838–46.PubMed
52.
go back to reference MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a fully-implanted, nickel-sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence. J Urol. 2019;201:967–72.PubMedCrossRef MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a fully-implanted, nickel-sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence. J Urol. 2019;201:967–72.PubMedCrossRef
53.
go back to reference Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I M, et al. Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn. 2022;41:539–51.PubMedCrossRef Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I M, et al. Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn. 2022;41:539–51.PubMedCrossRef
54.
go back to reference Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R, Yu O, Crane P, Larson E. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.PubMedPubMedCentralCrossRef Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R, Yu O, Crane P, Larson E. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.PubMedPubMedCentralCrossRef
55.
go back to reference An F, Yang X, Wang Y, Chen J, Wang J. OAB epidemiological survey of general gynaecology outpatients and its effects on patient quality of life. Neurourol Urodyn. 2016;35:29–35.PubMedCrossRef An F, Yang X, Wang Y, Chen J, Wang J. OAB epidemiological survey of general gynaecology outpatients and its effects on patient quality of life. Neurourol Urodyn. 2016;35:29–35.PubMedCrossRef
56.
go back to reference Zillioux J, Welk B, Suskind A, Gormley E, Goldman H. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41:1928–33.PubMedCrossRef Zillioux J, Welk B, Suskind A, Gormley E, Goldman H. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41:1928–33.PubMedCrossRef
57.
go back to reference Du C, Berg W, Siegal A, Huang Z, Jeong R, Hwang K, Kim J. Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology. 2021;153:119–23.PubMedCrossRef Du C, Berg W, Siegal A, Huang Z, Jeong R, Hwang K, Kim J. Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology. 2021;153:119–23.PubMedCrossRef
58.
go back to reference Malde S, Marcelissen T, Vrijens D, Apostilidis A, Rahnama’I S, Cardozo L, Lovick T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn. 2020;39(Suppl 3):S96–103.PubMed Malde S, Marcelissen T, Vrijens D, Apostilidis A, Rahnama’I S, Cardozo L, Lovick T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn. 2020;39(Suppl 3):S96–103.PubMed
Metadata
Title
Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices
Authors
Una J. Lee
Scott MacDiarmid
Catherine A. Matthews
Emily Gillespie
Kenneth M. Peters
Publication date
15-05-2024
Publisher
Springer Healthcare
Published in
Advances in Therapy
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02864-3
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine